Eisai US
Advancing Clinical Development Through Translational Precision
Keiji Furuuchi
Keiji Furuuchi, PhD, is a leader in data-driven pharmacology. He advances clinical development through translational science, biomarker research and regulatory insight. As Director of Preclinical Development at Eisai, he drives innovation across oncology and immunology, developing next-gen therapeutics like ADCs, AICs, molecular glues and cancer vaccines.
Shaping Oncology’s Future with Translational Precision
At Eisai, Furuuchi is pivotal in advancing oncology research from hypothesis to human trial. His work is not confined to laboratories or theoretical models. It lives at the point where science meets clinical impact, where preclinical signals are transformed into strategic decisions that influence global pipelines.
Furuuchi has helped accelerate some of Eisai’s most critical development programs by generating data that clarifies risk, validates the mechanism and strengthens regulatory engagement. His contributions have led to provisional patents, proof-of-concept models and decisive Go or No-Go calls that shape billion-dollar portfolios. By anchoring his work in scientific rigor and operational clarity, he enables discovery programs to move with purpose and precision.
Bridging Discovery and Development
Furuuchi approaches translational pharmacology with a systems mindset. He connects nonclinical insights with clinical endpoints, using biomarker-driven strategies to reduce uncertainty and increase program viability. Whether preparing for an IND or navigating early-stage regulatory review, he designs models that anticipate challenges long before they appear in trial data.
Furuuchi brings scientific discipline into conversations that often drift toward abstraction. He understands that a program's credibility rests not only on discovery but also on how that discovery is communicated, replicated and challenged
His work spans preclinical systems, including patient-derived xenografts and companion diagnostics built for resistance profiling. These tools help his teams stress-test molecules under conditions that mirror clinical complexity, allowing Eisai to adjust strategy without losing momentum. The result is a more resilient development path that balances scientific ambition with clinical discipline.
Driving Innovation with Purpose
Furuuchi’s focus extends beyond molecules. He shapes Eisai's thinking about modality and mechanisms as fundamental progress levers. From next-generation cancer vaccines to dual degraders and immunogenic triggers, he drives innovation not as a showcase but as a way to build safer, more innovative and more durable therapies.
Under his leadership, Eisai’s preclinical pharmacology has evolved into a strategic engine. It does not merely support clinical teams. It informs them, challenges them and in many cases leads them. He fosters alignment across academic labs, CROs and internal teams, ensuring every promising insight has a path to impact.
Where Science Meets Strategy
Furuuchi brings scientific discipline into conversations that often drift toward abstraction. He understands that a program's credibility rests not only on discovery but also on how that discovery is communicated, replicated and challenged. In regulatory conversations with the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japan Agency for Medical Research and Development (AMED), he delivers narratives grounded in data that speak across disciplines.
His strength is knowing that translational work is not a stage but a bridge. If built with care, that bridge can carry a therapy from concept to clinic faster than traditional routes allow. For Furuuchi, every experiment is part of a larger question: What will it take to make the next generation of cancer treatments not just possible but practical?
